AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that Edison, an investment research and advisory company with a world-renowned equity research platform and deep international healthcare expertise, has initiated equity research coverage of AlzeCure Pharma.
The research report by Edison is prepared by Dr. Jonas Peciulis and Dr. Sean Conroy, and was released on March 23, 2021. The report is available on the Edison website: www.edisongroup.com/publication/well-balanced-pipeline-for-alzheimers-and-pain/29111, and via AlzeCures website: www.alzecurepharma.se/en/section/investors/monitoring/
Sign up to receive research as it is published at: https://share.hsforms.com/111SE5IHAQhaa5z4Qq1VvdQ3k1vq
AlzeCure Pharma is also covered by Redeye, Vator Securities and Aktiespararna.